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Neonatal sepsis is common and is a major cause of morbidity and mortality. Vancomycin is the preferred treatment
of several neonatal staphylococcal infections. The aim of this study was to review published data on vancomycin
pharmacokinetics in neonates and to provide a critical analysis of the literature. A bibliographic search was
performed using PubMed and Embase, and articles with a publication date of August 2011 or earlier were included
in the analysis. Vancomycin pharmacokinetic estimates, which are different in neonates compared with adults, also
exhibit extensive inter-neonatal variability. In neonates, several vancomycin dosing schedules have been proposed,
mainly based on age (i.e., postmenstrual and postnatal), body weight or serum creatinine level. Other covariates
[e.g., extracorporeal membrane oxygenation (ECMO), indomethacin or ibuprofen, and growth restriction] of
vancomycin pharmacokinetics have been reported in neonates. Finally, vancomycin penetrates cerebrospinal fluid
(range=7-42%). Renal function drives vancomycin pharmacokinetics. Because either age or weight is the most
relevant covariate of renal maturation, these covariates should be considered first in neonatal vancomycin dosing
guidelines and further adjusted by renal dysfunction indicators (e.g., ECMO and ibuprofen/indomethacin). In
addition to the prospective validation of available dosing guidelines, future studies should focus on the relevance of
therapeutic drug monitoring and on the value of continuous vancomycin administration in neonates.
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INTRODUCTION
Neonates have a higher risk of nosocomial infections due to
humoral, cellular and myeloid cell functions combined with
the use of invasive techniques (e.g., central venous catheter
and endotracheal intubation) (1). Because neonatal bacterial
sepsis has mortality rates of 10-20% and causes morbidity
in 25-30% of survivors (2,3), effective and tolerated anti-
microbiologic treatment regimens are required. Coagulase-
negative Staphylococci and Staphylococcus aureus are common
nosocomial bacterial pathogens, and vancomycin is the
first-choice antibiotic to treat these pathogens, especially
in methicillin-resistance settings (4). Vancomycin is active
against gram-positive bacteria. Staphylococcus epidermis, in-
cluding methicillin-resistant strains, are inhibited by vanco-
mycin concentrations of 1-4 mg/ml. Staphylococcus pyogenes,
Streptococcus pneumonia, and Streptococcus viridans are suscep-
tible to 2 mg/ml vancomycin. Bacillus spp. are inhibited
by 2 mg/ml, Corynebacterium spp. by 0.04-3.1 mg/ml and
Clostridium spp. by 0.39-6 mg/ml vancomycin (5). Peak and
trough concentrations of vancomycin should be ,40 mg/ml
and ,10 mg/ml, respectively, to both be effective and avoid
oto- or nephrotoxicity in adults (6,7,8). Because vancomycin
activity is primarily time-dependent, the 24-h area under the
curve (AUC0-24h) divided by the minimum inhibitor concen-
tration (MIC) value (AUC0-24h/MIC) is a better predictor of
efficacy. In adults with MIC values less than 1 mg/ml, trough
concentrations greater than 10 mg/ml result in AUC0-24h/MIC
values .400.
In subsequent analyses addressing clinical pharmacology,
it is important to note that vancomycin is water-soluble, has
a limited plasma protein binding capacity (i.e., IgA and
albumin) and is mainly eliminated renally by glomerular
filtration, although its elimination is further modulated by
renal tubular transport (4). Compared with adults, neonates
have a higher extracellular fluid volume and a limited renal
elimination capacity (4,9). Consequently, vancomycin phar-
macokinetics are different in neonates and undergo sig-
nificant alterations as neonates mature. We aimed to
provide a summary of published observations on vanco-
mycin pharmacokinetics in neonates and a subsequent
discussion on areas of further research.
BIBLIOGRAPHIC SEARCH
The bibliographic search was performed electronically
using PubMed and Embase. Searches were performed with
the following keywords: "pharmacokinetics vancomycin
neonate’’; ‘‘continuous infusion vancomycin neonate’’;
Copyright  2012 CLINICS – This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
No potential conflict of interest was reported.
CLINICS 2012;67(7):831-837 DOI:10.6061/clinics/2012(07)21
831
‘‘ECMO vancomycin neonate’’; ‘‘indomethacin vancomycin
neonate’’; ‘‘ibuprofen vancomycin neonate’’; ‘‘vancomycin
penetration CSF neonate’’ and ‘‘vancomycin toxicity neonate’’
with the limit of ‘‘human’’. All studies published in August
2011 or earlier were included in the analysis. The bibliography
of each article was examined, and selected articles were read
carefully. In addition, the bookNeofax: a Manual of Drugs Used
in the Neonatal Care, by Young and Mangum (8), was
consulted. The bibliographic search resulted in 60 original
articles, 10 review articles, and two book chapters; the
publication year range was from 1961 to 2011.
RESULTS
Seventy-two studies were considered in this review.
Table 1 summarizes vancomycin dose guidelines based on
serum creatinine levels (10). Table 2 provides two neonatal
vancomycin-dosing strategies that are based on either
postmenstrual age or serum creatinine levels (11). Table 3
provides dosage guidelines based on postmenstrual age and
weight (12). Finally, Table 4 summarizes demographic and
pharmacokinetic parameters of vancomycin in neonates as
reported in the literature (12-27).
Median estimates of vancomycin pharmacokinetics
in neonates
Compared with pharmacokinetic estimates in adults, the
median distribution volume is higher in neonates, and the
highest estimates are in the most preterm neonates (Table 4).
In contrast, vancomycin clearance is significantly lower in
neonates compared with adults after correcting for body
surface area (27). When expressed in ml/min/kg, the
clearance estimates are lowest in the most preterm neonates
(0.98 ml/min/kg) (15). In addition, Table 4 illustrates that
there is at least a 2- to 3-fold difference in vancomycin
clearance within the neonatal age range, which in part
reflects maturation and other renal functions that are related
to co-morbidity characteristics in neonates (12-27).
Covariates that reflect maturation: creatinine, age
and/or weight
Vancomycin is almost exclusively cleared by renal
glomerular filtration because renal tubular functions are
still immature in neonates (4,9). Either postmenstrual age or
weight is a covariate of vancomycin clearance, presumably
because these covariates serve as indicators of glomerular
filtration rate maturation (28). Vancomycin clearance is
positively affected by weight, gestational age, postnatal age
and postmenstrual age and negatively affected by creatinine
levels (10-28). However, these covariates are interrelated
because postmenstrual age is the sum of gestational and
postnatal ages, whereas the correlation between weight
and age is self-evident. Finally, a progressive decline in
creatinine levels is associated with an increase in age
(Tables 1-4).
Covariates reflect comorbidity characteristics
The level of creatinine does not only reflect maturational
changes, but it may also in part reflect renal impairment. At
present, the use of neonatal creatinine levels to predict renal
function is controversial due to residual maternal creatinine
and bio-analytical issues (see the discussion section). Other
comorbidity characteristics that affect vancomycin clearance
are related to renal impairment, which are either primarily
caused by a drug-related reduction in renal clearance or a
lower endogenous renal clearance capacity or secondarily
caused by a disease-related decrease in renal function
(Table 4).
As documented by Frattarelli et al., growth restriction
affects vancomycin clearance capacity (17) in neonates (,28
days old), but this reduction in vancomycin clearance is
limited (16-20%) and related to the reduced renal elimina-
tion capacity of these neonates (19,29).
The association between patent ductus arteriosus (PDA)
and reduced vancomycin clearance is likely related to
pharmacological treatment with either ibuprofen or indo-
methacin. Either indomethacin or ibuprofen is administered
to induce PDA closure. Asbury et al. (26, Table 4) quantified
the impact of indomethacin on vancomycin clearance.
Basically, indomethacin administration for PDA closure
reduced vancomycin clearance by 50% (26). Allegaert (30)
aimed to quantify the impact of indomethacin or ibuprofen
on neonatal vancomycin clearance. Allegaert et al. con-
firmed the effect of indomethacin on vancomycin clearance
(-40%), whereas ibuprofen reduced clearance by 28%.
Therefore, indomethacin has a much higher effect on
vancomycin clearance compared with ibuprofen (30,31).
Seay et al. (21) reported on the population pharmacokinetics
of vancomycin in 192 patients and documented that dopa-
mine reduced vancomycin clearance (Table 4). In contrast,
when dopamine was evaluated as one of the covariates of
Table 1 - Vancomycin dosage guidelines developed by
Grimsley and Thomson (10).
Serum creatinine
concentration (mmol/l)
Vancomycin
(mg/kg) Interval (h)
20-29 20 8
30-39 20 12
40-49 15 12
50-59 12 12
60-79 15 18
80-100 15 24
.100 15 Check trough level at
24 h
Table 2 - Two neonatal vancomycin dosing strategies (postnatal age ,60 days) developed by Capparelli et al. (11).
Postmenstrual age (PMA) Serum creatinine concentration (Scr)
PMA (weeks) Dose (mg/kg) Interval (h) Scr (mg/dl) Dose (mg/kg) Interval (h)
#29 20 24 $1.7 15 48
30-33 20 18 1.3-1.6 10 24
34-37 20 12 1.0-1.2 15 24
38-44 15 8 0.7-0.9 20 24
$45 10 6 #0.6 15 12
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vancomycin clearance in a data set of 214 preterm neonates,
size, renal function and PMA, but neither dopamine nor
respiratory support, were major contributors to clearance
variability in premature neonates, which caused 18% of the
variability to be unexplained (28). Extra-corporeal membrane
oxygenation (ECMO) provides cardiopulmonary support for
patients with potentially reversible respiratory and cardiac
failure. Vancomycin clearance is decreased and its distribu-
tion volume is increased in neonates on ECMO (Table 4)
(24,25). Finally, an interaction at the level of competitive
binding or inhibition of renal tubular transport processes
likely explains the increase in vancomycin clearance during
amoxicillin-clavulanic acid co-administration in a cohort of 70
neonates (22).
Cerebrospinal fluid (CSF) pharmacokinetics of
vancomycin
Little is known concerning the penetration of vancomycin
in neonatal CSF. Reiter and Doron (32) reported CSF
concentrations in three vancomycin-treated neonates. The
case 1 subject was a 1264-g male who was delivered at 28
weeks of gestation, the case 2 subject was a 670-g male who
was delivered at 31 weeks of gestation, and the case 3
subject was a 1150-g female who was delivered at 26 weeks
of gestation. These three case subjects were treated with
vancomycin at a daily dose of 20 mg/kg for 14 days. The
article by Reiter and Doron (32) includes additional clinical
details. In case 1, the vancomycin CSF concentration was
5.6 mg/ml at 17.25 h after infusion on day 8 of therapy, and
the CSF penetration rate, which was measured by the CSF to
serum vancomycin concentration ratio, was 32%. In case 2,
the vancomycin CSF concentration was 2.2 mg/ml at 10.7 h
after intravenous administration on day 2 of the vancomy-
cin therapy, and the CSF penetration rate of vancomycin
was 26%. Patient 3 had a vancomycin CSF concentration of
5.5 mg/ml at 23 h after infusion on day 9 of the vancomycin
therapy, and the CSF penetration rate was 42%. Schaad et al.
(27) (Table 4) administered 10-15 mg of vancomycin
intravenously to three neonates whose gestational age
and body weight were unreported. The vancomycin CSF
concentration range was 1.2-4.8 mg/ml (mean= 3.1 mg/ml),
and the CSF penetration rate of vancomycin ranged from 7-
21% (mean= 14%). Finally, Pau et al. (33) reported the cases
of two newborns who had received vancomycin intrave-
nously and intra-ventricularly. The case 1 subject was a
1,280-g male who was born at 29 weeks of gestation and
suffered from several diseases. This patient received the
following vancomycin treatments: 50 mg/kg/day intrave-
nously and 5-10 mg intra-ventricularly. The duration of
vancomycin therapy was 26 days, and the vancomycin CSF
concentration range was 12.7-92.1 mg/ml. Patient 2 was a
female who was born at 31 weeks of gestation with multiple
congenital anomalies. This neonate received the following
vancomycin treatments: 60 mg/kg/day intravenously and
4 mg/day intraventricularly for 30 days. The vancomycin
CSF concentration range was 9.5-55.3 mg/ml.
DISCUSSION
Neonatal morbidity and mortality due to late-onset sepsis
caused by coagulase-negative staphylococci or methicillin-
resistant staphylococci has resulted in an increased necessity
for the effective and safe administration of vancomycin in
neonates. In the 1950s, Staphylococcus strains developed
resistance to treatment with penicillin. Vancomycin arose as
the treatment of choice for staphylococcal infections (34),
and its use declined in the 1960s when methicillin was
preferred because of its safer toxicity profile compared with
vancomycin (35). In 1978, the use of vancomycin resurfaced
as Streptococcus species developed further resistance to
cephalosporins and other penicillins (35).
At present, vancomycin is the current treatment of choice
for many neonatal staphylococcal infections. There are,
however, no reports yet on the association between indices
(i.e., peak, trough, and AUC0-24h) of vancomycin exposure
and either bactericidal effects or nephro- or ototoxicity in
neonates. Consequently, the target AUC0-24h/MIC index
($400) of vancomycin, which is documented in adults, is
used (36-39). Therefore, similar to a trough concentration of
10 mg/ml of vancomycin, the AUC0-24h/MIC target should be
considered for any dosage recommendation to minimize
treatment failure in neonates. Lustar and Metsvaht (38)
suggested that for mid-moderate neonatal infections, the
AUC0-24h/MIC ratio should be$400, and for severe infections
in immunocompromised hosts, such as cases of ventilator-
associated pneumonia sustained by Staphylococcus aureus, this
ratio should be $850. Staphylococcus warneri (40), which has
reduced glycopeptide susceptibility (MIC.2 mg/ml), also
requires a higher vancomycin exposure.
Obviously, this target necessitates the integration of the
most relevant vancomycin pharmacokinetic covariates in
neonatal dosing strategies. Van den Anker (39) stated that
the most important dosing strategies in neonates are based
on a combination of postmenstrual and postnatal ages,
which considers the known changes in body composition
and renal function with a higher dose for the treatment of
neonatal meningitis. Such strategies have been suggested or
evaluated by different groups.
Dosing guideline performance
Young and Mangum (8) suggested a vancomycin dosage
of 15 mg/kg every 12 h in meningitis patients and 10 mg/
kg every 12 h for the treatment of bacteremia. When the
postmenstrual age is #29 weeks, the vancomycin dose
should be administered every 12 or 18 h according to the
postnatal age (.14 days postnatal age or younger). When
the postmenstrual age range is 30-44 weeks, vancomycin
should be administered every 8 or 12 h according to the
postnatal age. When the postmenstrual age is $45 weeks,
vancomycin should be administered every 6 h. This dosing
guideline aims for a trough concentration between 5-10 mg/
ml. However, Badran et al. (41) recently illustrated that 51%
of the patients in their neonatal unit attained the desired
therapeutic trough concentration, and the trough concentra-
tion was ,5 mg/ml in 33% of the neonates when these
guidelines were utilized.
To further illustrate the difficulties of effective dosing
guideline implementation, we refer to the work of de Hoog
Table 3 - Initial vancomycin dosage guidelines in
neonates based on postmenstrual age (PMA) or weight,
developed by McDougal et al. (12).
PMA (weeks) Weight (g) Dose (mg/kg) Interval (h)
,27 ,800 18 36
27-30 800-1200 16 24
31-36 1200-2000 18 18
$37 .2000 15 12
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et al. (20). This group aimed to determine the best therapeutic
dose for the treatment of vancomycin-sensitive bacterial
infections in 108 neonates. The median gestational and
postnatal ages were 28.9 weeks and 14 days, respectively,
and the median body weight was 1,045 g (Table 4). The
vancomycin dose was 15 mg/kg every 12 h. Clearance was
Table 4 - Neonatal demographic data and pharmacokinetic parameters of vancomycin therapy. The results are
presented as the mean¡standard deviation unless otherwise stated.
Comments
GA
weeks
PNA
days
Weight
g n
Dose
mg/kg
Cl
ml/min/kg
Vd
l/kg tK h
Peak
mg/ml
Trough
mg/ml Reference
First dose 28.4
SD 2.6
20.5
SD 10.4
1069
SD 435
15 12.6
q24 h
1.22
SD 0.7
0.53
SD 0.13
6.0
SD 2.0
31.2
SD 12
9.5
SD 3.5
13
Steady state The values refer to the 26-case
population
+11 12.6
q24 h
1.16
SD 0.6
0.52
SD 0.10
6.6
SD 2.1
46.4
SD 15
19.4
SD 9.2
Group 1 26.6
SD 1.7
18
SD 8
908
SD 254
16 16
q24 h
1.1
SD 0.07
0.55
SD 0.02
6.6
SD 0.35
28.1
SD 1.2
3.0
SD 0.6
12
Group 2 29.4
SD 2.0
23
SD 14
1194
SD 412
15 18
q18 h
1.19
SD 0.08
0.56
SD 0.02
5.6
SD 0.36
27.9
SD 1.2
3.9
SD 0.6
Group 3 35.9
SD 3.7
24
SD 18
2405
SD 956
13 15
q12 h
1.36
SD 0.85
0.57
SD 0.02
4.9
SD 0.4
26.1
SD 1.3
5.5
SD 0.7
Preterm 25.9
SD 1.3
21a 769
SD 151
12 14.2
SD 3.2
0.8b 0.63
SD 0.025
10 hb 32.6
SD 9.3
5.7
SD 4.5
14
Group 1 29.5
SD 1.1
15.3
SD 5.9
1232
SD 263
13 Note A 0.98a 0.85a 11.3a 23.6a 10.5a 15
16
Group 2 30.1
SD 1.9
26.0
SD 14.2
1289
SD 265
12 Note A 0.89a 0.56a 8.7a 2 0.6a 9.9a
Preterm 26.5
SD 2.6
71a 880
SD 340
20 Note B 1.2b 0.68
SD 0.15
6.66b n.a. n.a.
SGA 27.3
SD 2.5
48
SD 38
1140
SD 590
20 n.a. 1.17a 0.52
SD 0.26
7.7
SD 4.9
31.5
SD 8.3
6.8
SD 4.2
17
AGA 26.5
SD 1.9
38
SD 47
1535
SD 986
123 n.a. 1.84a 0.72
SD 0.45
8.
0SD 6.4
30.6
SD 10.7
8.3
SD 6.4
GA 29 wks 29.3
SD 3.4
29
SD 20
1297
SD 640
15 Note C 1.07
SD 0.34
0.48
SD 0.09
5.6
SD 1.6
22.6
SD 3.6
7.6
SD 2.0
18
Population
kinetics
30
SD 2.4
.90%
, 2 wks
1000
SD 840
116 10 2.6a 0.52a 8.5a n.a. n.a. 19
Population
kinetics
28.9c 14c 1045c 108 15
q12 h
3.4
SD 0.11
0.43
SD .013
6.0
SD0.27
34.3
SD 7.7
8.2
SD 2.2
20
Population
kinetics
29.5
SD 5.1
16.5
SD 19.6
1492
1053
192 Note G 3.5a 0.76a 13.4-33.7
(range)
n.a. n.a. 21
Population
kinetics
32.2
SD 5.0
16.9
SD 10.9
1700
SD 800
70 15
q8-24
3.96a 0.57a 6.3a 7.5a ,20 22
Preterm and full-
term
31.0
SD 7.3
9.1
SD 4.9
1620
SD 550
11 Note F 0.74
SD 0.20
0.51
SD 0.03
7.2
SD 2.9
28.0
SD 5.4
4.9
SD 2.0
23
ECMO 38.8
SD 2.2
12.7
SD 5.1
3100
SD 600
15 10
q8 h
0.65
SD 0.28
0.45
SD 0.18
8.3
SD 2.2
27
SD 4.3
13.7
SD 2.7
24
Controls 39.7
SD 1.3
7.7
SD 2.3
3400
SD 400
15 10
q8 h
0.79
SD 0.41
0.39
SD 0.12
6.5
SD 2.1
23.0
SD 5.4
13.2
SD 4.5
ECMO 39
SD 1.4
1.6
SD 1.7
3300
SD 430
12 15-20 0.78
SD 0.19
1.1
SD 0.5
16.9
SD 9.5
30a 5- 10 25
Controls 29.3
SD 4.2
33.9
SD 19.9
1780
SD 1080
19 Note D 1.22
SD 0.54
0.52
SD 0.08
5.6
SD 1.2
27.8
SD 0.7
7.5
SD 1.2
26
PDA
(indo)
26.0
SD 1.2
17.6
SD 7.1
810
SD 160
4 Note E 0.61
SD 0.17
0.57
SD 0.06
11.9
SD 3.3
27.9
SD 0.4
8.5
SD 0.7
Preterm 32a 3.3a 1530a 7 10
q24 h
15
ml/min/
1.73 m2
0.74a 9.8a 16.8a 5.7a 27
Preterm 34a 4.7a 1570a 7 15
q24 h
27
ml/min/
1.73 m2
0.71a 5.9a 25.2a n.a.
Term 40a 2.6a 3070a 7 15
q24 h
30
ml/min/
1.73 m2
0.69a 6.7a 29.8a n.a.
GA=gestational age; PNA=postnatal age; n=number of cases; SGA= small for gestational age; AGA=appropriate for gestational age;
ECMO=extracorporeal membrane oxygenation; PDA=patent ductus arteriosus; n.a. = not available.
aMean, SD is not available; bExtracted figure; cMedian.
Note A: The vancomycin doses were 10, 15, or 20 mg/kg.
Note B: The vancomycin dose range was 9.2-18 mg/kg.
Note C: The loading dose was 15¡0.2 mg/kg, and the maintenance dose was 14.8¡4.3 mg/kg.
Note D: The loading dose was 15¡0.2 mg/kg, and the maintenance dose was 29.6¡13.1 mg/kg.
Note E: The loading dose was 15 mg/kg, and the maintenance dose was 14.8¡4. mg/kg.
Note F: The dose range was 12.1-13.8 mg/kg (12.6¡0.9 mg/kg), and the dosing interval range was 13-40 h (22.0¡7.5 h).
Note G: The dosing was initiated at 7.5, 10, 12, or 15 mg/kg, and the interval range was from q8 h to q24 h.
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0.057¡0.0018 l/h/kg (variability = 31%); the distribution
volume was 0.43¡0.013 l/kg (variability = 25%), and tK
was 6¡0.27 h (variability = 34%). Using this dosage (i.e.,
15 mg/kg every 12 h), 95.5% of the initial trough concentra-
tion measurements were in the desired therapeutic range.
Vancomycin trough concentrations before the second dose
were 8.2¡2.2 mg/ml. Trough concentrations before the fifth
dose were 12.3¡4.1 mg/ml. Only one trough concentration
measurement was below 5 mg/ml. The vancomycin trough
concentration range before the fifth dose was 15.3-20.6 mg/
ml. Vancomycin accumulates in serum; accordingly, after the
fifth dose, the peak concentration range was 16.6-34.5 mg/ml
(mean=25.8¡5.0 mg/ml). The vancomycin trough concen-
tration range was 5-15 mg/ml, and peak concentrations were
,40 mg/ml (39) (Table 4). The authors suggested that a
vancomycin dosage of 3610 mg/kg per day leads to a
minimized high peak serum concentration and a trough
serum concentration that is too low. However, this assertion
was derived from a prospective validation study of 22
neonates in the same unit. However, these results are
concomitant with the internal (same unit) prospective
validation efforts of Seay et al. (n = 20) and Marques-
Minana et al. (n = 41) (21,22).
Intermittent vs. continuous vancomycin
administration
Because the AUC concept aims to maintain the vanco-
mycin concentration above a given threshold, it has been
suggested that vancomycin can be administered as a
continuous infusion (42-45). Plan et al. (42) administered
vancomycin as a continuous infusion of 15-25 mg/kg/day
or 20-30 mg/kg/day to 145 neonates. The body weight
range of the neonates was 500-1,160 g, and their gestational
age range was 26-29 weeks. Using the abovementioned
dosage, bactericidal efficacy was maintained, and most
subjects had serum vancomycin concentrations within
the therapeutic range. Pawlotsky et al. (43) administered
vancomycin as a 24-h constant infusion to two neonatal
groups. Group 1 (n = 24) had a postmenstrual age range of
27-41 weeks and received 10-30 mg/kg/day according to
the postmenstrual age. Group 2 (n= 29) had a postmenstrual
age range of 28-51.5 weeks and received a loading dose of
7 mg/kg, followed by a continuous infusion of 10-40 mg/
kg/day according to the postmenstrual age. The mean
vancomycin serum concentrations at steady state were
11.0¡3.1 and 15.4¡6.2 mg/ml in Groups 1 and 2, respec-
tively. Both regimens were well tolerated. Oudin et al. (44)
confirmed the feasibility of this approach (i.e., a 7-mg/kg
loading dose and constant infusion of 30 mg/kg/day) but
suggested increasing the initial loading dose to 20 mg/kg,
which resulted in an exposure similar to that observed by
Pawlotsky et al. (43).
The use and limitations of therapeutic drug
monitoring
All pharmacokinetic studies demonstrate variability,
which is only in part explained by weight, age, or creatinine
level. This variability explains the use of therapeutic drug
monitoring (TDM) of trough concentrations to ensure
effectiveness and avoid nephrotoxicity. In contrast, the
quantification of peak concentrations provides no additional
monitoring value (4,8,39). Vancomycin-induced nephrotoxi-
city and ototoxicity were previously more common than is
currently observed. After eliminating impurities from the
early preparations of vancomycin, the incidence of primary
adverse effects, such as nephrotoxicity, ototoxicity and ‘‘red
man syndrome’’, was reduced (46). The most important risk
factors for developing nephrotoxicity are the following:
trough concentrations .10 mg/ml, concomitant treatment
with aminoglycosides and/or prolonged therapy (.21
days) (47,48). Other risk factors include high peak concen-
trations, high total dose, preexisting renal failure, and
concurrent treatment with amphotericin and/or furose-
mide. However, the role of these factors in the neonatal
population is not well-established (49). Proper vancomycin
TDM minimized both glomerular and tubular nephrotoxi-
city in two studies in children and neonates (8,39,50,51). In
most cases, nephrotoxicity is reversible, even after high
doses (52). In contrast, there is no proven association
between TDM and ototoxicity prevention (39).
Improving neonatal vancomycin effectiveness and
tolerance
Despite the number of reported pharmacokinetic studies
on vancomycin in neonates, there are still relevant issues
that require further consideration. First, covariates differ
between the different studies, and the prospective valida-
tion of dosing guidelines is limited but urgently required to
improve the predictability and extrapolation of dosing
guidelines. This may be partially related to analytical issues
specific to quantifying vancomycin or creatinine concentra-
tions. Immunoassays that are routinely used to quantify
vancomycin may overestimate vancomycin concentrations
because of the cross-reactivity with some of the vancomycin
degradation products or endogenous compounds, such as
bilirubin (53). The introduction of a more precise analytical
method, such as liquid chromatography-tandem mass
spectroscopy, should be considered. Creatinine levels ini-
tially increase and are most pronounced in the most
immature neonates (54). Postnatal observations also depend
on techniques used to quantify creatinine levels (i.e., Jaffe
colorimetry, compensated Jaffe quantification or enzymatic
quantification). It is generally accepted that the Jaffe
quantification method overestimates creatinine concentra-
tions because of bilirubin and cephalosporin interference.
This observation also indicates that the age- or weight-
dependent creatinemia reference values will differ based on
the quantification method used (55). Until recently, none of
the studies in the literature explicitly discussed creatinine
quantification methods.
Second, the external prospective validation of vancomy-
cin dosing guidelines is only a first step to improving the
efficacy and safety/tolerance of vancomycin. The AUC0-24h/
MIC ratio is derived from extrapolated data in adults and
necessitates prospective validation in neonates that includes
an analysis of the potential add-on value of continuous
administration with or without a loading dose (39). Finally,
data in specific settings, such as ECMO or meningitis, are
limited and warrant a focused approach (56). Until these
data emerge, there are no well-validated dosing guidelines
that can be used routinely throughout the world. Therefore,
we strongly recommend that neonatal units prospectively
validate one of the dosing guidelines provided (Tables 1-4).
Local validation efforts also enable caregivers to consider
the local MIC values of the isolated pathogens.
In conclusion, neonatal vancomycin pharmacokinetic data
were reviewed, which was followed by a critical analysis of
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the literature. Renal function drives vancomycin pharmaco-
kinetics. Consequently, age or weight are the most relevant
covariates of vancomycin clearance and should be consid-
ered first in neonatal vancomycin dosing guidelines and
further adjusted by indicators of renal dysfunction (e.g.,
ECMO and ibuprofen/indomethacin). In addition to the
prospective validation of vancomycin dosing guidelines that
includes an analysis of its effectiveness and tolerance, studies
should focus on the relevance and the methods applied for
therapeutic drug monitoring and on the value of continuous
vancomycin administration in neonates, whereas specific
settings (i.e., ECMO and ibuprofen/indomethacin) warrant
focused studies.
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